Life Tech Teams with SGC on Epigentic Antibodies | GenomeWeb

NEW YORK (GenomeWeb News) – Life Technologies has struck a collaborative partnership with the Structural Genomics Consortium to develop and release 200 highly specific epigenetic recombinant antibodies, the company said today.

The partners have now released 58 of these antibodies, a move that SGC Director and CEO Aled Edwards said in a statement marks "the first step toward developing the defacto standard set of quality epigenetics antibodies that researchers can use for generations to come."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.